NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
The Board of Directors approved the Buy Back of Equity Shares of the Company08-03-2023
NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
The Board of Directors approved the Buy Back of Equity Shares of the CompanyNatco Pharma to consider buyback of shares next week. Details here
Natco Pharma Ltd has informed Indian bourses that its board of directors are going to consider bonus shares in upcoming meeting scheduled on 8th March 2023NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for To Consider A Proposal For Buyback Of Fully Paid Up Equity Shares Of The Company
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/03/2023 ,inter alia, to consider and approve proposal for buyback of fully paid up equity shares of the CompanyNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches generic Pomalidomide Capsules in CanadaNATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
intimation for loss of share certificateNatco Pharma expecting 200 cr revenuefrom agri business in 12 months
In the January to March quarter, and, in the upcoming kharif season, we'll do extremely well, says CEO Rajeev NannapaneniNATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
information regarding issue of duplicate share certificateNatco Pharma submits application with USFDA for generic cancer drug
The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg.NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Company''s earnings conference call for Q3 FY23 held on 10th February, 2023NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO files generic Olaparib Tablets in USA